Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Clinical Experience with α-Particle–Emitting <sup>211</sup>At: Treatment of Recurrent Brain Tumor Patients with <sup>211</sup>At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6
393
Zitationen
9
Autoren
2007
Jahr
Abstract
This study provides proof of concept for regional targeted radiotherapy with (211)At-labeled molecules in oncology. Specifically, the regional administration of (211)At-ch81C6 is feasible, safe, and associated with a promising antitumor benefit in patients with malignant central nervous system tumors.
Ähnliche Arbeiten
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.
1981 · 14.248 Zit.
The nuclear receptor superfamily: The second decade
1995 · 6.967 Zit.
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
1984 · 5.023 Zit.
Screening λgt Recombinant Clones by Hybridization to Single Plaques in Situ
1977 · 4.664 Zit.
Abiraterone and Increased Survival in Metastatic Prostate Cancer
2011 · 4.377 Zit.